Bivatuzumab
Based on 1 Customer Validation
Bivatuzumab (BIWA 4) is a humanized monoclonal antibody targeting CD44v6. Bivatuzumab binds the v6 variant exon of CD44 with a Kd of 3.4 nM, undergoes internalization after binding, and achieves tumor localization. Bivatuzumab is inactive in antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. Bivatuzumab can serve as the antibody component for synthesizing antibody-drug conjugates (ADCs), such as Bivatuzumab mertansine (BIWI 1). Bivatuzumab can be used for research on head and neck squamous cell carcinoma or esophageal squamous cell carcinoma.
For research use only. We do not sell to patients.
- Purity : 99.82%
- CAS No.: 214559-60-1
- Molecular Weight:143.22 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD44
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-431 | IC50 |
8014 ng/mL
|
Competitive binding to CD44v6 on human A431 epidermoid carcinoma cells by cell ELISA with hMAb BIWA-4 incubated 30 mins and murine BIWA-1 competitor incubated 2 hrs, measured by absorbance at 450 nm.
Competitive binding to CD44v6 on human A431 epidermoid carcinoma cells by cell ELISA with hMAb BIWA-4 incubated 30 mins and murine BIWA-1 competitor incubated 2 hrs, measured by absorbance at 450 nm.
|
11992408 |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
186Re-labeled Bivatuzumab (400 µCi (100 µg); i.v.; single injection) reduces relative tumor volume in HNX-OE xenografts to a minimum of 80% at day 19 before tumor regrowth[1].
Bivatuzumab (highest dose level tested; i.v.; five daily doses; single cycle) has no effect on tumor growth in A431 and FaDu human SCC xenograft models[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of A431 cells labelling CD44 (red) with Bivatuzumab (anti-CD44) (HY-P99281). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/200 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 214559-60-1
-
Appearance Liquid
-
Molecular Weight 143.22 kDa
-
Color Colorless to light yellow
-
SMILES
[Bivatuzumab]
-
Synonyms
BIWA 4; Anti-CD44 Recombinant Antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Verel I, et al. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. International journal of cancer. 2002 May 20;99(3):396-402. [Content Brief]
[2]. Börjesson PK, et al. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3961S-72S. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Bivatuzumab
- 214559-60-1
- BIWA 4
- Anti-CD44 Recombinant Antibody
- BIWA4
- BIWA-4
- CD44
- ADC Antibodies
- In (Lu)-related protein p80
- Pgp-1/Ly-24
- ECMRIII
- HUTCH-1
- CD44v6
- esophageal squamous cell carcinoma
- head and neck squamous cell carcinoma
- internalization
- radioimmunotherapy
- squamous cell carcinoma
- tumor growth arrest
- tumor localization
- tumor regression
- xenograft
- Inhibitor
- inhibitor
- inhibit